Wednesday, 14 October 2026European Markets

QUESTERRE ENERGY Stock Bullish By 16% In The Last 5 Sessions

Loading stream...

(VIANEWS) - Shares of QUESTERRE ENERGY (Oslo Børs All-share Index_GI: QEC.OL) rose by a staggering 16% in 5 sessions from 1.61 kr to 1.87 kr at 04:39 EST on Friday, after five successive sessions in a row of gains. Oslo Børs All-share Index_GI is dropping 0.2% to 1,413.04 kr, after three sequential sessions in a row of losses.

QUESTERRE ENERGY's last close was 1.93 kr, 23.72% under its 52-week high of 2.53 kr.

About QUESTERRE ENERGY

Questerre Energy Corporation acquires, explores, and develops non-conventional oil and gas projects in Canada. It produces tight oil, oil shale, shale oil, and shale gas. The company primarily holds 40,800 acres located in Kakwa, west central Alberta, including a 25% working interest in 10,080 acres in Kakwa Central; 50% working interest in 4,480 acres in Kakwa North; 50% interest in 22,400 acres in Kakwa West; and 50% interest in 3,840 acres in Kakwa South. It also holds 100% working interest in 11,952 acres located in Antler, Saskatchewan; and oil shale assets in Jordan. The company was formerly known as Westpro Equipment Ltd. and changed its name to Questerre Energy Corporation in December 2000. Questerre Energy Corporation was incorporated in 1971 and is headquartered in Calgary, Canada.

Earnings Per Share

As for profitability, QUESTERRE ENERGY has a trailing twelve months EPS of -1.89 kr.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 2.54%.

More news about QUESTERRE ENERGY (QEC.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,372 source documents archived
Query this data → isubstrate.com